Currently, there are 113.88M common shares owned by the public and among those 97.86M shares have been available to trade.
The company’s stock has a 5-day price change of 22.40% and -29.49% over the past three months. FATE shares are trading -7.27% year to date (YTD), with the 12-month market performance down to -76.43% lower. It has a 12-month low price of $1.04 and touched a high of $8.83 over the same period. FATE has an average intraday trading volume of 3.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.12%, -5.04%, and -49.65% respectively.
Institutional ownership of Fate Therapeutics Inc (NASDAQ: FATE) shares accounts for 81.37% of the company’s 113.88M shares outstanding.
It has a market capitalization of $174.26M and a beta (3y monthly) value of 2.25. The earnings-per-share (ttm) stands at -$1.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.12% over the week and 8.25% over the month.
Earnings per share for the fiscal year are expected to increase by 0.43%, and -3.29% over the next financial year. EPS should grow at an annualized rate of 1.90% over the next five years, compared to -6.65% over the past 5-year period.
Piper Sandler coverage for the Fate Therapeutics Inc (FATE) stock in a research note released on June 17, 2024 offered a Overweight rating with a price target of $6. Wells Fargo was of a view on March 27, 2023 that the stock is Equal Weight, while H.C. Wainwright gave the stock Neutral rating on January 24, 2023, issuing a price target of $115- $7. Wedbush on their part issued Neutral rating on January 06, 2023.
